We have investigated the effect of the endogenous genotoxin malondialdehyde (MDA) on cell cycle kinetics and the expression and biochemical activity of several cell cycle regulatory proteins. MDA treatment of two human cell lines (RKO and H1299) resulted in a 3-to 6-fold elevation in the levels of the major detectable MDA-DNA adduct, M 1 G-dR. The increase in M 1 G-dR was accompanied by irreversible cell cycle arrest, elevation in p53 and p21 protein levels, and inhibition of cyclin E-and cyclin B-associated kinase activities. The decrease in cyclin Eand cyclin B-dependent kinase activities was caused by increased p21 and decreased cdc2 levels, respectively. Comparable levels of p21 induction were observed in RKO (wild-type p53) and H1299 (p53-null) cells. Thus, MDA was able to engage cell cycle checkpoint function in human cell lines when used at concentrations that produce M 1 GdR levels of the same magnitude found in human tissues.
Introduction
Malondialdehyde (MDA*) is an endogenous product of lipid peroxidation and eicosanoid biosynthesis (1) . It is mutagenic in bacterial and mammalian cells and carcinogenic in rodent models (2) (3) (4) (5) . In vitro, MDA reacts with deoxynucleosides to produce a variety of adducts (6) (7) (8) (9) (10) (11) . The major MDA-DNA adduct (a pyrimidopurinone produced from deoxyguanosine: M 1 G-dR) has been detected in DNA isolated from rodent and human tissues at levels from 3-150 per 10 8 nucleotides (12) . The high levels of this adduct in humans make it important to define the biological consequences of its formation and the defense system used to mitigate these effects. M 1 G-dR is mutagenic in Escherichia coli and slows the rate of DNA replication (13) . It is repaired by nucleotide excision repair in bacteria (13) and is likely to be a substrate for the mammalian excinuclease complex.
An important defense against DNA damage is the alteration of cell cycle kinetics to permit additional time for repair or the engagement of an apoptotic response (14) . To date, there is no information available regarding MDA effects on cell cycle progression or on its ability to induce apoptosis. Therefore, we examined the effect of MDA treatment on cell cycle kinetics and the expression and biochemical activity of several cell cycle regulatory proteins. The human cell lines used in this study, RKO and H1299, are wild-type and null for p53, respectively. Exposure of these cells to MDA concentrations that increased the levels of M 1 G-dR 3-to 6-fold led to an irreversible cell cycle arrest, an elevation of p53 and p21 proteins in a dose-dependent manner, and an inhibition of cyclin E-and cyclin B-associated cyclin-dependent kinase activities. Comparable effects of MDA on p21 expression were observed in RKO and H1299 cells. In contrast to its ability to induce cell cycle arrest, MDA did not induce apoptosis in either p53 wild-type or null cell lines. The induction of cell cycle arrest may be a defense mechanism against MDAinduced DNA damage irrespective of the cells' p53 status.
Materials and methods

DNA isolation and hydrolysis for gas chromatography-mass spectrometry (GC/MS) determination
The malondialdehyde-deoxyguanosine adduct M 1 G-dR was converted to a pentafluorobenzyl (PFB) derivative that was analyzed by gas chromatographyelectron capture negative chemical ionization mass spectrometry (GC/EC NCI/MS) as previously described (12, 15) . Briefly, after treatment with MDA (1 mM) for 24 h, RKO or H1299 cells were harvested by trypsinization and washed with phosphate-buffered saline (PBS) twice. Cell pellets were suspended in 50 mM MOPS buffer (pH 7.8) containing 25% sucrose, 10 µM BHA and 20 µM indomethacin. The samples were then frozen and thawed four times using a dry-ice/ethanol bath and a water bath maintained at 37°C. After centrifugation, the pellets were washed twice and resuspended in MOPS buffer. After adding an equal volume of lysis buffer (Applied Biosystems) containing BHA and indomethacin, samples were digested for 1 h with 138 units of RNase A (Sigma, St Louis, MO) then 3 h with 150 units of proteinase K (Sigma). DNA was isolated from the digest by phenolic extraction and ethanol precipitation.
DNA samples were dissolved in MOPS buffer. After an addition of 4 ng of D 2 -M 1 G-dR internal standard, a series of enzymes were added in the following order accompanied by a 37°C incubation: DNase I (1.5 h) (Calbiochem-Novabiochem, La Jolla, CA), nuclease P1 (2 h) (Sigma), and alkaline phosphatase (1 h) (Sigma). The DNA content of the original hydrolyzate was determined by HPLC analysis of the released deoxynucleosides. The MDA adduct was purified by immunoaffinity chromatography using a monoclonal antibody specific for M 1 G-dR (16) . The isolated M 1 G-dR was hydrolyzed to the base with formic acid (2.5% for 45 min at 60°C) and the PFB derivative was then prepared by purified silica solid phase extraction. The levels of adduct were determined by GC/EC NCI/MS (15) .
Cell culture condition and treatment
Human colorectal carcinoma (RKO) and human lung adenocarcinoma (H1299) cells were cultured at 37°C in an atmosphere of 95% air and 5% CO 2 in McCoy's 5A and F-12 medium, respectively (Gibco BRL Life Technologies, Gaithersburg, MD) that contained 10% bovine serum (Hyclone, Logan, UT), 50 units/ml penicillin and 50 µg/ml streptomycin. Cells were plated 24 or 48 h before treatment, and were 60-80% confluent at the time of treatment. Adriamycin (ADR) (0.4 µM) or MDA (1 mM) (ജ99% pure) was dissolved in fresh media prior to being added to cultures. Unless specified otherwise, cells were harvested after 24 h chemical treatment.
Protein lysate preparation and Western blot analysis
Cells were washed with ice-cold PBS twice, then lysed on ice for 30 min in a 0.5% Nonidet p-40 lysis buffer containing 50 mM Tris-HCl (pH, 7.5), 100 mM NaCl, and protease inhibitors antipain (10 µg/ml), leupeptin (10 µg/ml), pepstatin A (10 µg/ml) and chymostatin (10 µg/ml) (Sigma), and 4-(2-aminoethyl)-benzenesulfonylfluoride (200 µg/ml) (Calbiochem-Novabiochem). After scraping, total cell lysates were harvested and centrifuged at 13 000 g for 15 min. The supernatant was collected and protein concentration determined by bicinchoninic acid protein assay (Pierce, Rockford, IL). An aliquot of 50 µg of cellular protein was mixed with an equal volume of 2ϫ Laemmli sample buffer [125 mM Tris (pH 6.8), 10% β-mercaptoethanol, 20% glycerol, 4% sodium dodecylsulfate (SDS), and 0.05% bromophenol blue] and boiled at 100°C for 8 min. Cellular proteins were resolved using 12% SDS-PAGE and transferred onto polyvinylidene difluoride membranes (Millipore, Bedford, MA). For individual experiments, membranes were incubated with a 1:100 dilution of anti-p53 Ab-6 (Oncogene Research Products, Calbiochem, Cambridge, MA), anti-p21 WAF1 Ab-1 (Oncogene Research Products), anti-cyclin B1 GNS1 (Santa Cruz Biotechnology, Santa Cruz, CA), anti-cdc2 p34 (Santa Cruz Biotechnology), or anti-phospho-cdc2 (New England BioLabs, Beverly, MA) followed by incubation with a 1:20 000 dilution of secondary antibody. For the secondary antibody, either goat anti-mouse immunoglobulin (Ig)G horseradish peroxidase-conjugate (Pierce) or goat antirabbit IgG horseradish peroxidase-conjugate (Amersham, Arlington Heights, IL) was used. Detection was performed using enhanced chemiluminescence (ECL Western blotting detection system; Amersham).
Flow cytometric analysis
After trypsinization and two PBS washes, cells were fixed in 70% ethanol and incubated at -20°C for at least 1 h. Cells were resuspended in PBS, incubated with RNase (1 mg/ml) and stained with propidium iodide (50 µg/ml ) in the dark at room temperature for 30 min. Cell cycle determination was performed using a Becton Dickinson flow cytometer.
RNA isolation and Northern blot analysis
Total RNA was isolated using a RNAeasy™ kit (Qiagen, Chatsworth, CA) according to the manufacturer's instructions. Total RNA samples (12-15 µg) were denatured for 5 min at 70°C in a solution that contained 50% formamide, 17.5% formaldehyde, 20 mM MOPS, pH 7.0, 5 mM sodium acetate and 0.5 mM EDTA, pH 8.0. The RNA was size-fractionated on a 1% agaroseformaldehyde gel and assessed for equal loading by ethidium bromide-stained ribosomal RNA bands. The RNA was transferred onto a Hybond™-N nylon membrane (Amersham). Filters were pre-hybridized for 3-5 h at 42°C in a solution that contained 44% deionized formamide, 5ϫ SSC, 5ϫ Denhardt's solution, 0.5% SDS, 100 µg/ml denatured salmon testis DNA, and 50 µg/ml polyadenylic acid. Hybridization was performed in 1ϫ Denhardt's solution containing the same components as the pre-hybridization solution. An [α-32 P]dCTP random primed-labeled 2.1-kb p21 human cDNA fragment was used as a radioactive probe. After 9-14 h hybridization, the nylon membrane was washed under high stringency conditions (twice with 2ϫ SSC-0.1% SDS at 30°C for 5 min, and three times with 0.2ϫ SSC-0.1/% SDS at 45°C for 15 min). The hybridization bands were visualized using a Phosphorimager (Molecular Dynamics, Sunnyvale, CA) and normalized to 28S and 18S signals obtained on the same blot to control for variations in loading and transfer among samples.
Immunoprecipitation and kinase assays
Cell lysates (0.5-1.0 mg) were incubated with 50 µg rabbit IgG and protein A Sepharose beads (Pharmacia Biotech) for 1 h at 4°C with rocking. After centrifugation for 1 min (13 000 g), supernatants were collected and aliquotted for incubation with anti-cyclin B1 (GNS1) or anti-cyclin E antibody (Santa Cruz) for 1 h at 4°C. Antibody-protein mixtures were further incubated with protein A Sepharose for an additional 2 h at 4°C. Immunoprecipitates were washed three times with kinase lysis buffer (50 mM Tris-HCl, pH 7.4, 250 mM NaCl, 0.1% Triton X-100, 0.1% Nonidet P-40, 4 mM EDTA, 4 mM NaF, 0.1 mM sodium orthovanadate, 0.5 mM PMSF, and protein inhibitors (antipain, leupeptin, pepstatin A and chymostatin, 5 µg/ml, and 4-[2-aminoethyl]-benzenesulfonylfluoride [10 µg/ml; Calbiochem-Novabiochem]), and then twice with kinase buffer (50 mM Tris-HCl, pH 7.4, 10 mM MgCl 2 and 1 mM DTT). Washed immunoprecipitates were then combined with 10 µg of histone H1, 200 µM ATP and 2 µCi of [γ-32 P]ATP (3000 Ci/mmol; NEN) in 20 µl kinase buffer. After incubating at room temperature for 15 min, the kinase reaction was terminated by adding 20 µl of Laemmli sample loading buffer. Reaction mixtures were boiled and subjected to 12% SDS-PAGE. 32 Plabeled histone H1 bands were visualized and quantified using a PhosphorImager.
Results
Two human cell lines were used in this study: a human colorectal carcinoma cell line (RKO) that has wild-type p53, and a cell line derived from a human large cell lung carcinoma (H1299) that is genetically null for p53 (17) . In all experiments, adriamycin (ADR), an anthracycline antibiotic and genotoxic chemotherapeutic drug was used as a positive control. Previously, it has been shown that ADR treatment of cells increases p53 and p21 protein levels (18) . Although several investigations have suggested that anthracycline compounds exert their toxicity by intercalation in the DNA and stabilization of otherwise cleavable DNA-topoisomerase II complexes, the precise mechanism of action for these compounds remains to be defined (19) . The effect of MDA on H1299 cell growth was also studied ( Figure 1B ). After MDA treatment for 8 h, cells began to accumulate at G 2 /M, and reached a peak at 24 h with the percentage of cells in G 2 /M increased by 30% ( Figure 1B) . Furthermore, the induction of cell cycle arrest by MDA was dose dependent. After 24 h of treatment with 1 mM MDA, the percentage of cells in G 2 /M phase was 2-fold greater than that with 0.5 mM MDA in the H1299 cells (data not shown).
Malondialdehyde-deoxyguanosine (M 1 G) adduct levels
Irreversible cell cycle arrest after MDA or ADR treatment
Treatment of the cell lines with both MDA and ADR resulted in a pronounced G 2 /M phase block (Figure 1 ). To determine if the MDA-and ADR-induced cell cycle blocks were transient, were blocked in G 1 , 36% in S and 47% in G 2 /M. ADR treatment induced almost complete G 2 /M block with 87% of the cells accumulated at this checkpoint (ADR, Figure 2) ; no apparent release was observed after growth of the treated cells in fresh medium for 2 days. These results indicate that MDA and ADR induced an irreversible cell cycle arrest in RKO cells. Apoptosis was not detected in RKO cells with the doses of drugs used in the above experiments. However, apoptosis could be induced in RKO cells with a 4-fold higher concentration of ADR (1.6 µM) (data not shown).
Continual presence of MDA, but not ADR, is required for cell cycle arrest
To further address MDA effects on cell cycle kinetics, we determined if the continual presence of MDA and ADR was 
The percentage of cells arrested in G 2 /M phase from control and treated RKO cultures is shown in Figure 3 . A G 2 /M arrest was observed 24 h after MDA treatment. A longer MDA treatment (48 h) did not change the percentage of cells arrested in G 2 /M (data not shown); however, the accumulation of cells in G 2 /M was not observed when cells were treated with MDA for only 0.5 h, 1 h or 2 h followed by incubation in fresh medium for up to 24 h. In contrast, a 1 h treatment with ADR followed by a 24 h incubation in drug-free medium resulted in a significant cell cycle arrest at G 2 /M phase (~30% of the cells arrested). Maximal G 2 /M accumulation was seen after only 2 h of ADR and wash-out in drug-free medium for 24 h (~90% of cells arrested). In fact, the percentage of cells in G 2 /M after only 2 h ADR treatment was comparable with that seen with continual ADR treatment.
MDA elevates p21 and p53 protein levels in a dose-dependent manner
Since the prominent MDA-induced cell cycle arrest points were G 1 /S and G 2 /M, we hypothesized that MDA induces growth arrest through regulation of checkpoint proteins that control these cell cycle transitions. This hypothesis was first tested by examining the effect of MDA on two known cell cycle checkpoint proteins, p21 and p53. After exposure of RKO cells to increasing concentrations of MDA or ADR, p21 and p53 protein levels were evaluated in total cell lysates by Western blot analysis. The levels of p21 increased in a dosedependent manner in RKO cells after MDA treatment with maximal induction at a 1 mM dose ( Figure 4A ). However, p53 levels were only modestly elevated in RKO cells after a 1 mM dose of MDA. A decrease in p21 and p53 protein levels in the RKO cells was observed when the MDA dose was further increased to 4.4 mM ( Figure 4A ). This decrease is likely caused by cellular toxicity; in fact, the total protein levels from these cultures were significantly less than those from untreated cultures (data not shown).
The ADR-mediated induction of p53 and p21 followed a different pattern. After ADR treatment, p53 protein levels initially increased in a dose-dependent manner, reached a plateau between 0.4 µM and 0.8 µM drug, and decreased at higher doses ( Figure 4B) . A marked induction of p21 was seen after treatment with the lowest dose of ADR (0.08 µM). This induction remained constant until the concentration of ADR reached 1.6 µM and declined thereafter, probably because of cellular toxicity.
To determine if induction of p21 by MDA or ADR could occur in a p53-independent manner, H1299 cells (p53-null) were exposed to various concentrations of MDA or ADR, and p21 protein levels were analyzed. As expected, there was no detectable p53 protein expression in the H1299 cells ( Figure  5A and B). Nevertheless, a dose-dependent induction of p21 protein was seen after both MDA and ADR treatment. The MDA-induced elevation in p21 protein levels was comparable in H1299 and RKO cells (compare Figures 4A and 5A) . In contrast, a higher concentration of ADR (0.4 to 1.6 µM) was necessary to elevate p21 protein levels in the H1299 cells ( Figure 5B ). These results suggest that the increase in p21 after ADR treatment is probably caused by both a p53-dependent and -independent mechanism.
Time-dependent induction of p21 mRNA
Possible mechanisms by which MDA treatment could increase p21 protein levels include transcriptional (20) (21) (22) and posttranscriptional mechanisms (23) . Thus, the effect of MDA and ADR on p21 mRNA levels was measured. Total RNA was isolated from RKO cells after treatment with ADR (0.4 µM) or MDA (1 mM), for 2.5 h, 5 h, 9 h and 24 h. The level of p21 mRNA at each of these time points was analyzed by Northern blot analysis. The increase in p21 mRNA in the RKO cells ( Figure 6A ) was consistent with the protein increase ( Figure 4A ). Similar experiments were performed with the H1299 cells. The H1299 cells were treated with 1 mM MDA or 1.2 µM ADR for 4 h, 9 h and 24 h. Analogous to the results in the RKO cells, p21 mRNA levels increased in a time-dependent manner ( Figure 6B ). The MDA-induced elevation in p21 mRNA was consistent with the increase in p21 protein observed after MDA treatment ( Figure 5A ).
Effect of MDA and ADR on cyclin-dependent kinase activity
The effect of MDA on two enzymes known to be involved in G 1 /S and G 2 /M checkpoint regulation was next examined. The activation of p34 cdc2 kinase (cdc2), a serine-threonine protein kinase, is critical for progression of cells from interphase into M-phase (24, 25) . Cdk2 is another member of the cell cycledependent kinases that shares~60% homology with the cdc2 kinase, associates with cyclins A and E, and is involved in regulating the G 1 /S phase transition. Cyclin E-associated cdk2 activity rises in late G 1 , peaks in early S phase and regulates the G 1 -to-S phase transition (26) (27) (28) . Negative regulation of this enzyme complex is thought to play a key role in G 1 and S phase checkpoint function (18, 29) .
The effect of MDA treatment on cyclin E-dependent cdk2 kinase activity was determined by measuring the ability of cyclin-E immunoprecipitates from control and treated cells to phosphorylate a known substrate, histone H1 (29) . MDA treatment of RKO cells for 32 h resulted in an 83% reduction in the activity of cyclin E-associated cdk2 kinase as measured by this assay ( Figure 7A ). This reduction of cdk2 kinase activity was consistent with the G 1 /S cell cycle arrest observed after MDA treatment ( Figures 1A and 2A ) and the elevated levels of p21 protein ( Figure 5A ) that previously have been shown to bind and inactivate this enzyme complex in vitro and in vivo (20, (30) (31) (32) (33) (34) . ADR treatment of RKO cells resulted in a 68% decrease in the cyclin E-associated cdk2 activity. This result is again consistent with the ADR induction of p21 protein (Figure 5B ).
For G 2 /M phase transition control, the complex between p34 cdc2 (cdc2) and cyclin B appears to be the key regulator (25) . On formation of this complex, there is an activating phosphorylation of the cdc2 subunit at threonine 161; the complex is then held catalytically inactive by phosphorylations at threonine 14 and tyrosine 15 (35) . An inhibitory family of protein kinases that includes wee1 (36, 37) and myt1 (38) are thought to phosphorylate threonine 14 and tyrosine 15. Removal of these inhibitory phosphates by the cdc25C phosphatase leads to the activation of cyclin B-cdc2 and thereby induces entry into mitosis (39) . We analyzed whether the MDA-induced G 2 /M arrest in RKO cells ( Figure 1A ) correlated with a decrease in the activity of the cyclin B-dependent cdc2 kinase activity. The ability of cyclin B immunoprecipitates, from control and treated cells, to phosphorylate histone H1 was measured ( Figure 7B ). MDA treatment of RKO cells for 32 h resulted in a marked decrease (65%) of cyclin Bdependent cdc2 kinase activity as compared with untreated controls. This decrease in cyclin B-associated kinase activity was consistent with the induced G 2 /M arrest ( Figure 1A) .
In contrast, ADR treatment of RKO cells did not have an inhibitory effect on cyclin B-associated kinase activity. In fact, there was a 25% increase in cyclin B-associated kinase activity after ADR treatment ( Figure 7B ). This was surprising, considering that~90% of the cells arrested at the G 2 /M boundary after ADR treatment ( Figure 1A) .
Possible mechanisms by which MDA treatment could decrease cyclin B-cdc2 activity include transcriptional and post-translational modifications of cyclin B, cdc2 or other proteins that regulate this complex (e.g. cdc25C or wee1). Total protein was extracted from RKO cells 32 h after treatment and subjected to Western blot analysis to monitor cyclin B and cdc2 protein levels (Figure 8 ). No change in the steady state level of cyclin B was seen after 24-32 h of MDA treatment. However, a decrease in the total cdc2 protein content was apparent after 32 h of exposure. Also, an increase in a slower migrating species of cdc2 appeared after ADR treatment. This species is indicative of post-translational modification by phosphorylation ( Figure 8 ). As tyrosine 15 is an important target for inhibitory phosphorylation of cdc2 (35) , an antiphosphotyrosine antibody specific for cdc2 phosphorylated at the tyrosine 15 residue was used to confirm tyrosine phosphorylation of cdc2. While ADR treatment led to an increase in phosphorylated cdc2, MDA did not increase the levels of phosphorylated cdc2; rather, there appeared to be a reduction in the phosphorylated species cdc2 after MDA treatment as compared with the control (Figure 8 ). This result is consistent with the reduction in total cdc2 protein. Thus, it is likely that MDA decreases cdc2 kinase activity through reduction of cdc2 protein levels.
Discussion
Primary events after exposure of eukaryotic cells to DNA damaging agents include activation of certain signaling pathways that may eventually result (depending on the extent of DNA damage) in cell cycle arrest at checkpoints (14, 40) . It is hypothesized that there is a relationship between DNA damage, cell cycle arrest and inhibition of cell division, although the molecular mechanism of such a relationship remains to be clearly defined for each type of DNA damage. Information about how different cyclin-cdk complexes are inhibited after specific types of DNA damage in normal cells is important for our understanding of how cancer cells escape this cell cycle checkpoint function. In the present study we have investigated the effect of an endogenous mutagen and carcinogen, MDA, on cell cycle kinetics and the expression of proteins involved in checkpoint processes. The results obtained are consistent with the paradigm that DNA-damaging agents induce checkpoint cell cycle arrest, inhibition of cdk activity and alteration in the function of cdk-cyclin complexes.
Our experiments demonstrate that MDA treatment of human cells resulted in the disruption of cell cycle-associated events. MDA treatment of asynchronously growing human colorectal carcinoma cells (RKO) and human lung adenocarcinoma cells (H1299) resulted in 3-to 5-fold increase in M 1 G-dR adduct formation and cell cycle arrest at G 1 , S and G 2 /M, with the predominant block at G 2 /M. High concentrations of MDA (1 mM) were required to exert these effects. This is probably because MDA exists as its conjugate base at physiological pH and is negatively charged. This reduces MDA uptake by cells and its reaction with DNA. However, the levels of M 1 G-dR detected in MDA-treated cells in this study are comparable with the levels of M 1 G-dR found in human tissue (12) .
The cell cycle arrest induced by MDA was irreversible. RKO cells released from 24 h MDA treatment were unable to re-enter the cell cycle, even after 48 h. Forty-eight hours is sufficient time for~3 cycles of cell division in RKO cells (~15 h cell cycle traverse time) (data not shown). The growth inhibitory effect of MDA was accompanied by a dose-dependent increase in p21 and p53 protein levels. In the H1299 cells, the MDA-induced increase in p21 occurred through a p53-independent mechanism. This result is consistent with previous studies that demonstrated p53-independent induction of p21 after induction of cellular oxidative stress (41) .
In order to determine if RKO and H1299 cells were more sensitive to disruption of cell cycle associated events at specific phases of the cell cycle (G 1 , S or G 2 /M), we attempted to synchronize the cultures with mimosine and aphidicolon, two standard chemical inhibitors of the cell cycle (Gilbert et al., 1995) . The intent was to synchronize the cells and examine cell cycle kinetics after release in the presence or absence of MDA. However, treatment of the RKO and H1299 cells with the synchronization agents resulted in a significant increase in the levels of p53 and p21 proteins in the RKO cells, and p21 protein in the H1299 cells (42). Since we were not able to separate the effects of MDA from those induced by the synchronization agents, we limited our studies to asynchronous cultures of cells.
Consistent with the observed MDA-induced cell-cycle arrest, we detected decreases in cyclin-associated cdk activities. MDA treatment of asynchronously growing cells resulted in a measurable decrease in both cyclin E-dependent cdk2 and cyclin B-dependent cdc2 activities, which is consistent with the cell cycle blockade that occurs at G 1 /S and G 2 /M. The MDA-mediated increase in p21 protein levels and inhibition of cdk2 activity are consistent with previous studies that demonstrate p21 inhibition of cyclin E-cdk2 activity (20, (30) (31) (32) (33) (34) . Furthermore, the importance of p21 as an effector of the G 1 /S checkpoint in response to DNA damage is supported by the recent observation that irradiation-induced cell cycle arrest is compromised in p21-deficient mouse embryo fibroblasts (43, 44) .
We also noted an S-phase block after treatment of H1299 cells with MDA. In addition to its effect on cdk activity, p21 can interfere with replicative DNA synthesis. In a SV40-based in vitro DNA replication system, p21 has been shown to bind to proliferating cellular nuclear antigen (PCNA), and to impair the processive movement of DNA polymerase δ during DNA chain elongation (45, 46) . Distinct domains of p21 mediate effects on cdk inhibition and PCNA binding (47) (48) (49) . In these in vitro DNA replication models, p21 inhibits replicative DNA synthesis but does not interfere with the role of PCNA in excision-repair DNA synthesis (50) . Likewise, p21 has been demonstrated to play a role in DNA repair in vivo (51) . This has led to the hypothesis that p21 coordinates cell cycle arrest in response to DNA damage through the inhibition of the cdks and at the same time mediates an arrest of replicative DNA synthesis, which allows damage responsive repair. Results from the present study are consistent with these previous studies, in that induction of p21 after MDA treatment was associated with an arrest of replicative DNA synthesis in vivo.
The data presented in this report demonstrate that the G 2 /M cell cycle arrest induced by MDA was coupled to inhibition of the activation of cyclin B-dependent cdc2 kinase activity. This result is consistent with other studies that have shown that a variety of DNA-damaging agents are capable of arresting the G 2 /M phase transition through regulation of the cdc2 pathway (52) (53) (54) . Ionizing radiation leads to transient tyrosine phosphorylation of cdc2 (55) and the downregulation of cyclin B RNA (56, 57) , whereas, nitrogen mustard prevents the initiation of the autocatalytic feedback loop of cdc2 activation by cdc25C (52) .
It is unlikely that the MDA-mediated decrease in cdc2 kinase activity was caused by p21 association in the cyclin Bcdc2 complex. In previous studies, p21 was found in very low, if detectable, levels in the cyclin B-cdc2 protein complexes immunopurified from cells arrested in G 2 /M after ultraviolet radiation (34), ADR (P.M.Flatt and J.A.Pietenpol, unpublished results) or ionizing radiation (P.M.Flatt and J.A.Pietenpol, unpublished results). Furthermore, G 2 /M blockade after DNA damage has been shown in cells that are genetically null for p21 (58) . Our results indicate that MDA-induced disruption of the cell cycle at G 2 /M correlated with a reduction in cdc2 protein levels and, thus, enzymatic activity. This reduction in cdc2 protein could be caused by MDA-induced changes in RNA or protein synthesis or degradation. Also, the reduced level of tyrosine-phosphorylated cdc2 observed after MDAtreatment could be due, in part, to decreased association between cyclin B and cdc2, which would also lead to a smaller fraction of tyrosine-phosphorylated cdc2. Nonetheless, the effect of MDA on cdc2 protein appears to be relatively specific since the levels of several other proteins analyzed in this study were not reduced after MDA treatment. Induction of G 2 /M phase checkpoint arrest through reduction of cdc2 protein levels defines a new biochemical mechanism for inhibition of cdc2 kinase activity after treatment of cells with a DNA damaging agent.
The present findings describe a mechanism that links oxidative stress to control of cell cycle progression. The polyunsaturated fatty acid residues of phospholipids are important targets for oxygen radical damage and MDA is a major product of lipid peroxidation (1, 59, 60) . Furthermore, MDA is generated by arachidonic acid metabolism via the cyclo-oxygenase pathway and cyclo-oxygenase overexpression is associated with tumorigenesis in some tissues (61) (62) (63) (64) . Previous studies have shown that MDA is mutagenic and carcinogenic and that it generates several different adducts when it reacts with DNA (6-11). One of these adducts, M 1 G-dR, has been detected at significant levels in liver and leukocyte DNA from healthy human beings (12, 15) . The levels of M 1 G-dR detected in human liver and rodent liver are~4-fold higher than the levels induced by MDA treatment of RKO or H1299 cells in the present experiments (12) . Thus, endogenous levels of DNA damage by MDA are high enough in some human tissues to trigger p53 induction, p21 induction, and to induce G 1 , S, and G 2 /M cell cycle arrest. The checkpoint blocks induced in the tissue culture cells by MDA are irreversible. These data suggest that division will be prevented in cells that have undergone significant oxidative stress in vivo. In normal cells this may serve a protective role against the induction of mutation. However, MDA generation and DNA adduction may also provide strong selective pressure for the outgrowth of cells that are resistant to its cell cycle inhibitory effects, and thus, contribute to tumorigenesis.
